Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553155 | 0.88 | PTGS2 (0.46) | PTGS2 | |
| SCHEMBL21552932 | 0.88 | PTGS2 (0.38) | PTGS2PTGS1 | |
| SCHEMBL21553016 | 0.84 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL21553004 | 0.78 | PTGS2 (0.34) | PTGS2 | |
| SCHEMBL21552981 | 0.77 | PTGS2 (0.35) | PTGS2ALDH1A1CYP1A2 | |
| SCHEMBL21564838 | 0.77 | PTGS2 (0.35) | PTGS2ALDH1A1CYP1A2 | |
| SCHEMBL21553034 | 0.75 | KDM1A (0.42) | PTGS2PTGS1 | |
| SCHEMBL21564886 | 0.75 | ALDH1A1 (0.35) | PTGS2ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL21553043 | 0.73 | PTGS2 (0.35) | PTGS2ALDH1A1CYP1A2 | |
| SCHEMBL23258119 | 0.73 | CYP1A2 (0.35) | ALDH1A1CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | Imago Biosciences. Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1A, KDM1B, KDM2A | PTGS2 2929/4885PTGS1 1984/4885ALDH1A1 599/4885 |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | PTGS2 2832/4885PTGS1 2259/4885ALDH1A1 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.